^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NFKB2 negative

    i
    Other names: NFKB2, Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells 2 (P49/P100), Lymphocyte Translocation Chromosome 10 Protein, Nuclear Factor NF-Kappa-B P100 Subunit, DNA-Binding Factor KBF2, Oncogene Lyt-10, P49/P100, LYT-10, NF-KB2, H2TF1, LYT10, Nuclear Factor Of Kappa Light Polypeptide Gene Enhancer In B-Cells 2, Nuclear Factor Of Kappa Light Chain Gene Enhancer In B Cells 2, Nuclear Factor NF-Kappa-B P52 Subunit, Nuclear Factor Kappa-B, Subunit 2, Transcription Factor NFKB2, NFKB,
    Entrez ID:
    4791
    2years
    Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR) (ASH 2022)
    We found that NFKB2-ANK and -DD are crucial at initiating bortezomib's apoptotic signal by facilitating caspase-8 activation (unpublished data). Interim analysis demonstrates a trend higher efficacy and significantly better PFS in ixazomib with dexamethasone in MM patients with negative NFKB2 break-apart FISH compared to those with a positive test. Efficacy and toxicity of the triplet regimen are somewhat lower than what is seen in the Tourmaline 1 trial. This study is registered clinicaltrials.gov# NCT02765854
    Clinical • P2 data
    |
    CASP8 (Caspase 8) • NFKB2 (Nuclear Factor Kappa B Subunit 2)
    |
    NFKB2 negative
    |
    lenalidomide • bortezomib • Ninlaro (ixazomib) • dexamethasone
    3years
    Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR) (ASH 2021)
    We found that NFKB2-ANK and -DD are crucial at initiating bortezomib's apoptotic signal by facilitating caspase-8 activation (unpublished data). Interim analysis demonstrates a trend higher efficacy and ≥G3 toxicity of ixazomib with dexamethasone in MM patients with negative NFKB2 break-apart FISH compared to those with a positive test. Efficacy and toxicity of the triplet regimen are comparable to what is seen in the Tourmaline 1 trial. This study is registered clinicaltrials.gov# NCT02765854
    Clinical • P2 data
    |
    CASP8 (Caspase 8) • NFKB2 (Nuclear Factor Kappa B Subunit 2)
    |
    NFKB2 negative
    |
    lenalidomide • bortezomib • Ninlaro (ixazomib) • dexamethasone